Company intelligence / Profile preview
Altamira Therapeutics
Hamilton, -, Bermudaaltamiratherapeutics.com ↗
- Ownership
- Public · CYTO
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Altamira’s two flagship siRNA programs—AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis—are both in preclinical development beyond in vivo proof of concept. The company has demonstrated successful nanoparticle-based delivery of circular RNA and continues to expand its platform applications. Legacy clinical-stage assets have been divested or outlicensed.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- siRNAmRNAcircular RNA (circRNA)peptide-based nanoparticle delivery systems
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Nuance Pharma (East/South East Asia distribution)Pharma NordicUnivercells Group collaboration on mRNA vaccine delivery using SemaPhore platformradiopharmaceutical targeting collaboration announced Jan 2025
Beyond the preview
Go deeper on Altamira Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altamira Therapeutics.